On Tuesday, H.C. Wainwright reaffirmed its positive stance on shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ:ESPR), maintaining a Buy rating and a $16.00 price target for the company's stock. Currently trading at $3.10, the stock has shown remarkable momentum with a 20.62% gain in the past week.
According to InvestingPro data, analyst targets range from $2.05 to $16.00, reflecting diverse market opinions about this $610 million market cap company. The firm's endorsement follows Esperion's recent announcement regarding the submission of new drug applications for NEXLETOL and NEXLIZET to Health Canada on December 2.
These filings aim to address the considerable medical need for heart disease treatments in Canada, where approximately 2.6 million adults live with diagnosed heart disease.
The analyst highlighted the significance of the Canadian market for Esperion's therapies, noting the substantial number of individuals affected by heart disease according to the Canadian Chronic Disease Surveillance System. Esperion's global expansion strategy for its BDA franchise is also advancing, with several key developments noted.
InvestingPro analysis reveals impressive revenue growth of 187% over the last twelve months, with additional ProTips and detailed financial metrics available for subscribers. In Taiwan, regulatory approval was granted for Otsuka Pharmaceuticals to market NILEMDO, while in Japan, Otsuka is planning to submit a New Drug Application (NDA) by the end of 2024, with approval and pricing expected in 2025.
Moreover, Esperion is looking forward to potential regulatory filings or partnerships in Australia and Israel in the first half of 2025. These strategic moves are part of the company's broader international growth strategy, which also emphasizes its commitment to commercial development.
The analyst's reiteration of the Buy rating and price target reflects confidence in the strong momentum of Esperion's BDA franchise. Based on InvestingPro's Fair Value analysis, the stock appears to be trading near its fair value, with a comprehensive financial health score rated as "GREAT."
In other recent news, Esperion Therapeutics has been making considerable strides in the pharmaceutical industry. The company's new cholesterol drug, bempedoic acid, has submitted a New Drug Application in Japan, following a successful Phase 3 trial.
Moreover, Esperion has submitted New Drug Submissions to Health Canada for two cholesterol-lowering medications, NEXLETOL and NEXLIZET.
Esperion's financial performance has also been noteworthy, with a 53% year-over-year increase in U.S. net product revenue, totaling $31.1 million in the third quarter of 2024. Total (EPA:TTEF) revenue rose to $51.6 million, up from $34 million in the previous year. This growth was driven by the expansion of their product labels, strategic partnerships, and an expansion of payer coverage to over 165 million patient lives.
The company has monetized European royalties, repaid debts, and reported a 17% increase in total retail prescription equivalents. Despite facing gross-to-net headwinds, Esperion has expanded the labels for its products, NEXLETOL and NEXLIZET. As these are recent developments, investors should keep a close eye on the company's performance in the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.